A new blood test, Stockholm3, detected 90% of aggressive prostate cancer cases in clinical trials, outperforming the traditional prostate-specific antigen (PSA) test, which identified 74%. According to a study published in the Annals of Internal Medicine, the test could improve early detection of curable disease while reducing unnecessary biopsies and MRIs for men aged 50 to 74.
How Stockholm3 Outperforms Standard PSA Screening
The PSA test has served as the standard for prostate cancer screening since the 1990s, but it carries significant diagnostic limitations. Dr. Hari Vigneswaran, chief medical officer of A3P Biomedical, notes that the PSA test often contributes to over-diagnosis of non-aggressive cancers while simultaneously missing a substantial share of aggressive disease. In contrast, the Stockholm3 test assesses a man’s risk of aggressive prostate cancer.
When aggressive prostate cancer is found while still confined in the prostate, the five-year survival rate is close to 100%. Early identification remains the most critical factor in successful treatment outcomes.
What the Karolinska Institutet Study Reveals
Researchers at the Karolinska Institutet in Sweden monitored over 12,000 men aged 50 to 74 over a two-year period to evaluate the test’s efficacy. During this follow-up, 443 participants were diagnosed with aggressive prostate cancer. Thorgerdur Palsdottir, a researcher at the Karolinska Institutet’s Department of Medical Epidemiology and Biostatistics, stated that Stockholm3 identifies significantly more aggressive cases without increasing the number of unnecessary follow-up procedures.

Why Early Detection Trends Are Shifting
Data from the National Cancer Institute’s SEER database indicates that metastatic prostate cancer has risen over the past decade. This trend suggests that we have not improved early detection of the aggressive, curable disease that screening is meant to catch. By improving the specificity of initial screenings, researchers aim to reduce the reliance on unnecessary MRIs and biopsies.
Pro Tip: Understanding Screening Limitations
Even with advanced blood tests like Stockholm3, experts emphasize that a biopsy remains the gold standard for confirming the disease. Always consult with a urologist to discuss your specific risk factors.
Frequently Asked Questions
- Is Stockholm3 available in the U.S.? No, it is an investigational device and is not currently available for sale in the U.S.
- How does Stockholm3 differ from a PSA test? Stockholm3 is a blood test that estimates a man’s risk of aggressive prostate cancer, while PSA has been the standard screening tool since the 1990s.
- Will this replace the need for a biopsy? No. While the test can help determine who needs further examination, a biopsy remains the gold standard for confirming the disease.
Are you interested in the latest advancements in oncology and preventative health? Subscribe to our health newsletter for weekly updates on clinical trial breakthroughs and medical research.














